CompletedPhase 2NCT01526356
Topical Rapamycin to Erase Angiofibromas in TSC
Studying Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of Texas Health Science Center, Houston
- Principal Investigator
- Mary Kay Koenig, MD, MDThe University of Texas Medical School at Houston
- Intervention
- Placebo(drug)
- Enrollment
- 179 enrolled
- Eligibility
- All sexes
- Timeline
- 2012 – 2014
Study locations (10)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UCLA Mattel Children's Hospital, Los Angeles, California, United States
- Jack & Julia Center for TSC at Oakland Children's Hospital & Research Center, Oakland, California, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Herscot Center for Adults and Children with TSC Massachusetts General Hospital, Boston, Massachusetts, United States
- Clinic Without Walls, Saint Paul, Minnesota, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Texas Scottish Rite Hospital, Dallas, Texas, United States
- The University of Texas Medical School at Houston, Houston, Texas, United States
- Sydney Children's Hospital, Sydney, New South Wales, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01526356 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07561957A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) GuidelinesSt. James's Hospital, Ireland
- RECRUITINGPHASE1NCT07369505Sapu003 in Advanced mTOR-sensitive Solid TumorsSAPU NANO (US) LLC
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06392009Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type IIGRIN Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT02461459Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)Boston Children's Hospital
See all trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis →